Similarly, in patients with advanced NSCLC and PD-L1 expression ≥ 50%, the combination of first-line cemiplimab (a PD-1 inhibitor) and chemotherapy significantly improves OS and PFS [423]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.